Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...
ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...